Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Continued Dosing of Oritavancin for Complicated Gram-Positive Infections.

Literature DB >> 33328715

Continued Dosing of Oritavancin for Complicated Gram-Positive Infections.

Jodi Meyer¹, Paul Lata¹, Susanne Barnett¹.

Abstract

Several retrospective and cohort analyses have suggested that continued dosing of oritavancin is both safe and efficacious for complicated Gram-positive infections, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

Entities: Chemical Disease Species

Year: 2020 PMID： 33328715 PMCID： PMC7735458 DOI： 10.12788/fp.0068

Source DB: PubMed Journal: Fed Pract ISSN： 1078-4497

14 in total

1. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Authors: Samira Dahesh; Brian Wong; Victor Nizet; George Sakoulas; Truc T Tran; Samuel L Aitken
Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191

Review 2. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.

Authors: Daniel B Chastain; Anthony Davis
Journal: Int J Antimicrob Agents Date: 2018-12-08 Impact factor: 5.283

3. Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Authors: Debora Sweeney; Audrey Stoneburner; Dean L Shinabarger; Francis F Arhin; Adam Belley; Greg Moeck; Chris M Pillar
Journal: J Antimicrob Chemother Date: 2016-11-17 Impact factor: 5.790

4. Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.

Authors: Lucas T Schulz; Emily Dworkin; Jennifer Dela-Pena; Warren E Rose
Journal: Pharmacotherapy Date: 2017-12-11 Impact factor: 4.705

5. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.

Authors: Anne H Norris; Nabin K Shrestha; Genève M Allison; Sara C Keller; Kavita P Bhavan; John J Zurlo; Adam L Hersh; Lisa A Gorski; John A Bosso; Mobeen H Rathore; Antonio Arrieta; Russell M Petrak; Akshay Shah; Richard B Brown; Shandra L Knight; Craig A Umscheid
Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079

6. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Authors: G Ralph Corey; Samantha Good; Hai Jiang; Greg Moeck; Matthew Wikler; Sinikka Green; Paul Manos; Richard Keech; Rajesh Singh; Barry Heller; Natalia Bubnova; William O'Riordan
Journal: Clin Infect Dis Date: 2014-10-06 Impact factor: 9.079

7. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.

Authors: Dino J Delaportas; Sandy J Estrada; Matthew Darmelio
Journal: Pharmacotherapy Date: 2017-07-02 Impact factor: 4.705

8. Single-dose oritavancin in the treatment of acute bacterial skin infections.

Authors: G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan
Journal: N Engl J Med Date: 2014-06-05 Impact factor: 91.245

9. The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.

Authors: Mark Redell; Miguel Sierra-Hoffman; Maha Assi; Markian Bochan; David Chansolme; Anurag Gandhi; Kathleen Sheridan; Ivan Soosaipillai; Thomas Walsh; Jill Massey
Journal: Open Forum Infect Dis Date: 2019-11-04 Impact factor: 3.835

10. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.

Authors: Jennifer A Johnson; Eoin R Feeney; David W Kubiak; G Ralph Corey
Journal: Open Forum Infect Dis Date: 2015-10-29 Impact factor: 3.835

1 in total

Review 1. Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.

Authors: Xiangyi Cui; Yuhong Lü; Changwu Yue
Journal: Infect Drug Resist Date: 2021-12-21 Impact factor: 4.003

1 in total